Unicycive Therapeutics, Inc.
UNCY · XNASCIK 1766140fmd_1VJ4DQ6M2TM1HPBX9B4BSR1QY2Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Jun 30, 2026, 26 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | – | – | 1 | 1 | – | – |
| Research and development | 1 | 6 | 12 | 13 | 20 | 9 |
| Selling, general and administrative | 0 | 0 | 0 | – | – | – |
| Total operating expenses | 2 | 9 | 19 | 21 | 32 | 30 |
| Operating income | (2) | (9) | (18) | (21) | (32) | (30) |
| Interest expense | 0 | 1 | 0 | 0 | 0 | 0 |
| Interest and investment income | – | – | – | 1 | 1 | 1 |
| Other non-operating income (expense) | (0) | (1) | (0) | (10) | (5) | 3 |
| Net income | (2) | (10) | (18) | (31) | (37) | (27) |
| Net income to common shareholders | – | (10) | (18) | (31) | (38) | (27) |